The Latest Cardiac and Vascular News
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship […]
— Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO — — Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR, […]
Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics Pre-clinical study showed that IMB-101 improves cardiac contractile function and fibrosis post-myocardial infarction, highlighting its therapeutic potential in the context of myocardial ischemia and heart failure BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical […]
AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]
Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data […]
Minimally-invasive, implant-free technology for heart failure patients studied at 1 and 3 months AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved […]
Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offering of common stock yielding $60.1 million in net proceeds May 13, 2021 04:00 PM Eastern Daylight Time MALVERN, Pa. […]
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital technology company in healthcare data management, is pleased to announce the appointment of seven cardiac electrophysiologist professionals as members of the company’s medical advisory board. As PaceMate™ continues forward in its mission to advance efficient digital healthcare solutions through innovative technology and its compassion-driven […]
May 14, 2021 Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing […]
– Operating loss decreased vs. Q1 2020 – Net loss increased vs. Q1 2020 – ZanthoSyn® revenues decreased vs. Q1 2020 – Company pursuing multiple funding opportunities HONOLULU, May 14, 2021 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 […]
